This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eckstein, A Articles by Esser, J Search for Related Content PubMed PubMed Citation Articles by Eckstein, A Articles by Esser, J Topic Collections Relevant Article

Impact of smoking on the response to treatment of thyroid associated ophthalmopathy

¹ Department of Ophthalmology, University of Essen, Germany
² Department of Medicine, Division of Endocrinology
³ Department of Hygiene and Occupational Medicine

Correspondence to:
Correspondence to:
Anja Eckstein, MD, University Essen, Department of Ophthalmology, Hufelandstrasse 55, 45122 Germany;
anja.eckstein{at}uni-essen.de

Background: In patients with Graves’ disease, smoking considerably increases the incidence and severity of thyroid associated ophthalmopathy (TAO). The authors sought to determine if smoking also influences the course of TAO during treatment, and the efficacy of therapy.

Methods: 41 smokers and 19 non-smokers with moderate untreated TAO were included in this prospective study. All patients were treated with steroids and, 6 weeks after the beginning of drug therapy, with orbital irradiation. Follow up was performed 1.5, 4.5, 7.5, and 12 months after the beginning of the study. Proptosis, clinical activity score (CAS), and motility were evaluated. The extent of smoking was derived from the concentration of the haemoglobin adduct N-2-hydroxyethylvaline (HEV), a parameter of long term smoking.

Results: There was no difference in the clinical manifestations of TAO between smokers and non-smokers at the beginning of treatment. However, CAS decreased (p<0.05) and motility improved (p<0.02) significantly faster and to a greater extent in non-smokers than smokers. Inverse correlations between the CAS decrease and the HEV levels observed 4.5 and 7.5 months after the beginning of treatment and between the improvement of motility and the HEV levels after 1.5, 4.5, and 7.5 months indicated a dose dependence. Mean HEV levels did not vary much during the follow up period and were significantly different in smokers (mean 5.4 (SD 2.7) µg/l) and non-smokers (mean 1.8 (1.3) µg/l; p<0.01).

Conclusion: Smoking influences the course of TAO during treatment in a dose dependent manner. The response to treatment is delayed and considerably poorer in smokers.

Keywords: thyroid associated ophthalmopathy; smoking; haemoglobin adducts

Relevant Article

BJO at a glance

Creig Hoyt
Br. J. Ophthalmol. 2003 87: 663. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				N Lois, E Abdelkader, K Reglitz, C Garden, and J G Ayres Environmental tobacco smoke exposure and eye disease Br. J. Ophthalmol., October 1, 2008; 92(10): 1304 - 1310. [Abstract] [Full Text] [PDF]

				T. J. Cawood, P. Moriarty, C. O'Farrelly, and D. O'Shea Smoking and Thyroid-Associated Ophthalmopathy: A Novel Explanation of the Biological Link J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 59 - 64. [Abstract] [Full Text] [PDF]

				A. K. Eckstein, M. Plicht, H. Lax, M. Neuhauser, K. Mann, S. Lederbogen, C. Heckmann, J. Esser, and N. G. Morgenthaler Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves' Ophthalmopathy and Help to Predict Severity and Outcome of the Disease J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3464 - 3470. [Abstract] [Full Text] [PDF]

				G. E Krassas and W. Wiersinga Smoking and autoimmune thyroid disease: the plot thickens. Eur. J. Endocrinol., June 1, 2006; 154(6): 777 - 780. [Abstract] [Full Text] [PDF]

				A. J. Dickinson, B. Vaidya, M. Miller, A. Coulthard, P. Perros, E. Baister, C. D. Andrews, L. Hesse, J. T. Heverhagen, A. E. Heufelder, et al. Double-Blind, Placebo-Controlled Trial of Octreotide Long-Acting Repeatable (LAR) in Thyroid-Associated Ophthalmopathy J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5910 - 5915. [Abstract] [Full Text] [PDF]

				T. Cawood, P. Moriarty, and D. O'Shea Recent developments in thyroid eye disease BMJ, August 14, 2004; 329(7462): 385 - 390. [Full Text] [PDF]